Truvada Lawsuit Filed Against Gilead Over Unlawful Scheme To Maintain Uncompetitive Pricing of HIV Drug

Irvin Jackson

Add Your Comments

Gilead illegally bribed a generic competitor to delay a competing version of the blockbuster HIV drug Truvada, according to a class action lawsuit filed by investors in the drug manufacturer.

The complaint (PDF) was filed in the U.S. District Court for the Northern District of California on September 17, presenting claims for the Jacksonville Police Officers and Fire Fighters Health Insurance Trust, as well as other similarly situated investors.

The Truvada lawsuit outlines an alleged scheme between Gilead Sciences, Inc. and Cipla Ltd. and Cipla USA, which claims Gilead bribed Cipla not to release a generic version of Truvada, instead giving them a license to product a lesser known HIV drug, Atripla, or providing them a license to produce Hepatitis C drugs in India.

HIV DRUGS LAWSUITS

Did you suffer kidney injuries or bone fractures on Truvada or other TDF-based HIV drugs?

Gilead HIV drugs Truvada, Atripla, Stribild, Viread and Complera have been linked to increased risks of kidney and bones injuries, which lawsuits allege may have been avoided if safer formulations had not been withheld by the manufacturer.

Learn More
SEE IF YOU QUALIFY FOR COMPENSATION
Truvada-HIV-Drug-Lawsuit
Truvada-HIV-Drug-Lawsuit

HIV DRUGS LAWSUITS

Did you suffer kidney injuries or bone fractures on Truvada or other TDF-based HIV drugs?

Gilead HIV drugs Truvada, Atripla, Stribild, Viread and Complera have been linked to increased risks of kidney and bones injuries, which lawsuits allege may have been avoided if safer formulations had not been withheld by the manufacturer.

Learn More
SEE IF YOU QUALIFY FOR COMPENSATION

According to the complaint, this allowed Gilead to continue selling Truvada at premium prices without generic competition.

The class action lawsuit, and others like it, note that Gilead constructed a web of joint development agreements, preventing its co-conspirators from competing against Gilead’s tenofovir disoproxil (TDF) based drugs.

Truvada, however, is the flagship of this family of HIV drugs. In addition to its role as an HIV treatment, Truvada is also the go-to preventative HIV treatment, known as pre-exposure prophylaxix (PrEP).

The lawsuit is the latest in a growing number of claims filed against Gilead, claiming the company acted unscrupulously and illegally to keep profit margins high on its HIV drugs.

In addition to sweetheart deals made with competing drug companies to stifle competition. Critics say Gilead also held back the release of a safer formulation in order to maximize profits from Truvada and similar drugs until the patents ran out.

Gilead faces a growing number of individual Truvada lawsuits filed by users of the HIV drug who have experienced bone and kidney problems caused by tenofovir disoproxil fumarate (TDF) contained in the medication.

Those plaintiffs claim that Gilead knew about a safer alternative in 2004, known as tenofovir alafenamide (TAF), which is used in Descovy and other drugs introduced in recent years, yet held off on development of the newer drugs until Truvada and other TDF-based drugs started facing generic competition.

Irvin Jackson
Written by: Irvin Jackson

Senior Legal Journalist & Contributing Editor

Irvin Jackson is a senior investigative reporter at AboutLawsuits.com with more than 30 years of experience covering mass tort litigation, environmental policy, and consumer safety. He previously served as Associate Editor at Inside the EPA and contributes original reporting on product liability lawsuits, regulatory failures, and nationwide litigation trends.

Tags: Class Action, Gilead, HIV, HIV Drugs, Truvada

More HIV Drugs Lawsuit Stories

0 Comments

This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

JPML Sets Hearing Over Spinal Cord Stimulator Lawsuit Consolidation For May 28
In late May, a panel of federal judges will hold oral arguments over whether all federal spinal cord stimulator lawsuits should be consolidated before one judge for pretrial proceedings.
Fire Pit Burn Lawsuits Mount as CPSC Issues Warning Over New Flame Jetting Injuries, Death
As the number of lawsuits over tabletop fire pits continues to grow, the CPSC has issued a warning indicating that despite a consumer’s death linked to one product, the manufacturer has not agreed to remove the devices from the market.
Depo-Provera Meningioma Warning Update Should Be Added to Birth Control Shot Lawsuit
A Depo-Provera meningioma lawsuit argues that Pfizer had a duty to warn women about scientific evidence linking the birth control shot to potential brain tumor growth yet failed to do so.